INDV
Indivior Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$34.88
−2.27%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- $1.07
- Revenue estimate
- $330.5M
Latest reported
- Last report date
- Aug 3, 2026
- EPS actual
- $1.15
- EPS estimate
- $0.87
- Revenue actual
- $343.0M
- Revenue estimate
- $306.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +65.5%
- Revenue beats (12Q)
- 10
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 3, 2026 | $0.87 | $1.15 | Beat 32.34% | $343.0M |
| Apr 30, 2026 | $0.64 | $0.96 | Beat 50.00% | $317.0M |
| Oct 30, 2025 | $0.39 | $0.72 | Beat 87.01% | $314.0M |
| Jul 31, 2025 | $0.27 | $0.51 | Beat 92.45% | $302.0M |
| Apr 24, 2025 | $0.22 | $0.41 | Beat 83.04% | $266.0M |
| Feb 20, 2025 | $0.32 | $0.32 | In line | $299.0M |
| Oct 24, 2024 | $0.31 | $0.54 | Beat 74.19% | $307.0M |
| Jul 25, 2024 | $0.40 | $0.44 | Beat 10.00% | $299.6M |
| Apr 25, 2024 | $0.42 | $0.37 | Miss -11.90% | $282.7M |
| Feb 22, 2024 | $0.28 | $0.43 | Beat 53.57% | $300.7M |
| Nov 9, 2023 | $0.30 | $0.34 | Beat 13.33% | $261.2M |
| Jul 27, 2023 | $0.22 | $0.39 | Beat 77.27% | $279.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026